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Background: Potential non-invasive markers of pouchitis would have a great deal of significance
within clinical practice. Aim: This study is aimed at assessing the diagnostic accuracy of fecal
calprotectin and matrix metalloprotease-9 as potential markers in patients both with and
without pouchitis. Patients and methods: Stool and blood samples were collected from 33 ileal
pouch-anal anastomosis patients before a follow-up pouchoscopy. Biopsy samples were taken
for histological purposes. The presence of cuffitis and stenosis was evaluated with an endoscopy.
Calprotectin and matrix metalloprotease-9 were quantified with an enzyme-linked
immunosorbent assay. Results: Pouchitis was detected in 30.3% of the patients. The levels of
fecal calprotectin and matrix metalloprotease-9 increased significantly in patients with pouchitis.
The sensitivity and specificity of matrix metalloprotease-9 was higher than that of fecal
calprotectin. Only matrix metalloprotease-9 correlated significantly with the severity of pouchitis.
Discussion: Fecal matrix metalloprotease-9 has a high specificity in the diagnosis of pouchitis.
KEYWORDS: fecal calprotectin • ileal pouch-anal anastomosis • matrix metalloprotease-9 • pouchitis, ulcerative colitis
Background
A severe flare-up requiring hospitalization and
intravenous steroid therapy develops in
approximately 15% of patients with ulcerative
colitis (UC) at least once during the course of
the disease. Approximately 30% of patients
with relapsing, extensive UC require surgery [1].
Total proctocolectomy with ileal pouch-anal
anastomosis (IPAA) has been the most com-
mon and potentially curative surgical proce-
dure for intractable UC since 1978, although
up to 50% of the patients who undergo this
surgery develop pouchitis [2]. The incidence of
pouchitis is high and increases over time after
pouch formation. The study by Simchuk et al.
determined the short- and long-term outcomes
of patients undergoing IPAA, revealing that
the incidence of pouchitis in patients who
were followed for 6 months, 1 year and 3 years
was 25, 37 and 50%, respectively. The inci-
dence of pouchitis was 94% in patients who
were followed for more than 6 years [3]. How-
ever, according to other studies, the reported
cumulative frequency of pouchitis 10–11 years
after IPAA surgery ranges from 23 to 46%
[2,4,5]. Suzuki et al. found the cumulative risk
of pouchitis to be 10.7% at 1 year, 17.2% at
2 years, 24.0% at 5 years and 38.2% at
10 years [6].
The clinical symptoms of pouchitis include
watery and/or bloody diarrhea, abdominal dis-
comfort, urgency and incontinence, occasionally
accompanied by extraintestinal manifestations [7].
If symptoms persist, the presence of cuffitis –
the inflammation of the rectal cuff – should
also be considered. For the standardized defini-
tion of pouchitis, Sandborn et al. developed the
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pouchitis disease activity index (PDAI) in 1994, which includes
clinical, endoscopic and histological criteria [8]. The current gold
standard for assessing the severity of pouch inflammation is an
endoscopy with biopsies. However, non-invasive methods for
detecting the onset of pouch inflammation in order to differenti-
ate between pouchitis and cuffitis, to monitor disease activity and
to determine treatment efficacy during the follow-up would have
a high clinical value and could help make the diagnosis without
an endoscopy, which would be much more comfortable for
the patients.
Fecal calprotectin (FC), a diagnostic stool marker of neutro-
philic intestinal inflammation, correlates with endoscopic and
histological disease activity in adults and children afflicted by
inflammatory bowel disease (IBD) and also appears to be a
good predictor of relapse in IBD, mainly in UC [9–11]. Matrix
metalloprotease-9 (MMP-9), one of the zinc-dependent
enzymes participating in the normal mucosal defense, is also
abundantly released by neutrophils in IBD. MMP-9 levels have
been shown to be significantly increased in the stool of UC
patients compared to healthy control patients and patients with
irritable bowel syndrome, and it correlates to a high degree
with the clinical and endoscopic activity of UC, as well as with
FC [12]. Only limited data are available on the diagnostic accu-
racy of FC in pouchitis, and this is the first study to examine
the sensitivity of MMP-9 in pouch inflammation.
Aim: The aim of our prospective study is to evaluate the
diagnostic accuracy of FC and MMP-9 in colectomized UC
patients with and without pouchitis, assessed by clinical, endo-
scopic and histological scores.
Patients & study design
Study population
Overall, 33 patients (female/male ratio: 18/15; median age at
UC diagnosis: 25.5 years, interquartile range (IQR): 19.5–
34.3; median age at surgery: 36.5 years, IQR: 26.8–46; median
time elapsed after pouch formation: 43.5 months, IQR: 21.3–
72.8) undergoing proctocolectomy with IPAA at the University
of Szeged were consecutively enrolled in the study between
March 2012 and May 2013. IPAA was performed in two steps
requiring a temporary ileostomy for an average of 6 months.
The level of the IPAA was at 3 to 4 cm above the dentate line.
Disease activity was evaluated by PDAI [8], which includes the
clinical, endoscopic and histological assessment of the disease.
Pouchitis was defined as a PDAI score of >7. The severity of
the suspected pouchitis was also estimated by the physician
based on the symptoms of the patients admitted to the First
Department of Medicine, University of Szeged. A day before
pouchoscopy, patients were asked to provide fecal samples once
at the First Department of Medicine, Szeged, Hungary. Blood
samples were also obtained during the outpatient visit. Before
pouchoscopy, the physician assessed in each patient if pouchitis
was present or not on the basis of clinical symptoms only.
Scoring system of PDAI is detailed in TABLE 1.
Blood inflammatory markers, FC & MMP-9 measurements
Routine laboratory methods were used to determine C-reactive
protein and serum iron levels, hematocrit, hemoglobin levels
and the thrombocyte count.
Stool samples were obtained and stored at -20˚C until the
determination of FC and MMP-9 levels. For calprotectin meas-
urements, fecal specimens were thawed at 4˚C. Calprotectin
levels were quantified with an enzyme-linked immunosorbent
assay (Quantum Blue, Bu¨hlmann Laboratories Ltd, Scho¨nen-
buch), according to the manufacturer’s instructions. For
MMP-9 measurements, 1 g of the fecal samples was diluted,
mixed and homogenized in 4 ml of ice-cold Tris–buffer
(0.15 m NaCl + 20 mm Tris–HCl, pH 8.3) and then centri-
fuged. MMP-9 was also measured with a quantitative enzyme-
linked immunosorbent assay (R&D Systems, Abingdon, UK).
Detection limit for FC and MMP-9 was 30 mg/g and
0.156 ng/ml.
Pouchoscopy, histological examination
The participants underwent pouchoscopy performed by a sin-
gle, experienced endoscopist (TM) to evaluate the macroscopic
inflammation of the pouch. The presence of cuffitis and possi-
ble stenosis of the lower surgical anastomosis was also evaluated
Table 1. Scoring system of pouchitis disease activity
index.
Criteria Score
Clinical
• Stool frequency
– Usual postoperative stool frequency
– 1–2 stools/day > postoperative usual
– 3 or more stools/day > postoperative usual
• Rectal bleeding
– None or rare
– Present daily
• Fecal urgency or abdominal cramps
– None
– Occasional
– Usual
• Fever (temperature >37.8oC)
– Absent
– Present
• Endoscopic inflammation
– Edema
– Granularity
– Friability
– Loss of vascular pattern
– Mucous exudates
– Ulceration
• Acute histologic inflammation
– Polymorphic nuclear leukocyte infiltration
Mild
Moderate + crypt abscess
Severe + crypt abscess
• Ulceration per low-power field (mean)
– >25%
– 25–50%
– >50%
0
1
2
0
1
0
1
2
0
1
1
1
1
1
1
1
1
2
3
1
2
3
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with endoscopy. Cuffitis was defined as inflammation of the
rectal cuff in the area between the anastomosis and the dentate
line on endoscopy and histological examination, with or with-
out minimal inflammation of the pouch body [13].
Biopsy samples from the reservoir were taken for histological
purposes. Histological variables, including the degree of poly-
morphonuclear leukocyte infiltration and the extent of ulcera-
tion, were scored by a single pathologist (LT).
Statistical analyses
Correlations between FC, MMP-9 and PDAI and blood test
results were determined with Pearson’s correlation test or
Spearman’s rank. Frequencies and continuous variables were
compared with Fisher’s exact test and the Mann–Whitney U-
test. Predictors of pouchitis were assessed using multivariate
logistic regression analysis. A p value of less than 0.05 was
considered statistically significant. The cut-off levels, specific-
ity and sensitivity were calculated using receiver operating
characteristic analysis. The cut-off level was calculated in case
the value of the area under the receiver operating characteris-
tic curve (AUC) was above 0.89, which was determined
based on the maximum value of Youden’s index (sensitivity +
specificity - 1).
Ethical considerations
The study protocol was approved by the Ethical Committee of
the University of Szeged. All subjects provided written and
informed consent to participate.
Results
Frequency of pouchitis
Pouchitis determined by PDAI was detected in 10 out of the
33 (30.3%) patients. The median PDAI was 10 in the case
of pouchitis and 1 if no inflammation was observed in the
pouch (p < 0.0001). Cuffitis occurred in 14 patients and ste-
nosis developed in 12 patients. Of the 14 cases of cuffitis,
pouchitis was also present in four patients and stenosis in
five. The median endoscopic subscores of PDAI were
3.5 and 0, and the median histological subscores of PDAI
were 4 and 0 in patients with and without pouchitis, respec-
tively. According to the physicians’ estimations, the presence
of pouchitis was suspected in 16 patients. The diagnosis of
pouchitis was confirmed in 10 patients, whereas the clinical
symptoms were proved to be caused by cuffitis in the remain-
ing six cases where pouchitis was not confirmed endoscopi-
cally. The clinical characteristics of patients enrolled in the
study are detailed in TABLE 2.
FC levels in patients with and without pouchitis
Median FC concentration was significantly higher in patients
with (560 mg/g) versus without (96.5 mg/g) pouchitis
(p = 0.009) (FIGURE 1). The cut-off value for FC in the diagnosis
of pouchitis was 262 mg/g with a sensitivity of 67% and a
specificity of 89% (AUC = 0.78) (FIGURE 2). Negative predictive
value and positive predictive value of FC were 84 and 78%,
respectively, in the diagnosis of pouchitis. However, no correla-
tion was shown between FC concentration and the severity of
pouchitis (r = 0.188; p = 0.348). Although, when examining
the subscores of PDAI (stool frequency, rectal bleeding, fecal
urgency, fever, endoscopic inflammation and histological sub-
scores), the endoscopic and histological subscores showed sig-
nificant association with FC concentration (p = 0.0001;
p = 0.0002). FC was determined in every patient.
Fecal MMP-9 levels in patients with and without pouchitis
The median fecal MMP-9 level was significantly higher in
patients with (16.9 ng/ml) versus without (1.34 ng/ml) pouchi-
tis (p = 0.004) (FIGURE 3). For MMP-9, the cut-off value was
3.85 ng/ml with a sensitivity of 89 and a specificity of 91%
Table 2. Clinical characteristics of patients with and
without pouchitis enrolled in the study.
Patients with
pouchitis
(n = 10)
Patients without
pouchitis
(n = 23)
Median age at onset
(years)
23 28
Median age at the time
of the study (years)
30 40
Median disease duration
at IPAA
4 9
Female/male ratio 5/5 13/10
Presence of cuffitis 4 10
Presence of stenosis 2 10
Median time elapsed
after pouch formation
(months)
38 47
Median PDAI 10 1
Subscores of PDAI
(median values)
– Stool frequency
– Rectal bleeding
– Fecal urgency
– Fever
– Endoscopic
Inflammation
– Histological subscore
1
0
1.5
0
3.5
4
0
0
0
0
0
0
Medication for pouchitis
Antibiotics (ciprofloxacin
and/or metronidazole)
Methylprednisolone
Infliximab
10
4
4
–
–
–
Median FC (mg/g)† 560 96.5
Median fecal MMP-9
(ng/ml)†
16.9 1.34
†FC was determined in 33, MMP-9 in 21 patients.
FC: Fecal calprotectin; IPAA: Ileal pouch-anal anastomosis; MMP: Matrix
metalloprotease-9; PDAI: Pouchitis disease activity index.
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(AUC = 0.89) (FIGURE 4). Negative Predictive Value and Positive
Predictive Value of fecal MMP-9 were 90 and 89%, respec-
tively, in the diagnosis of pouchitis. A statistically significant
correlation was shown between the fecal MMP-9 concentration
and the severity of pouchitis (r = 0.526, p = 0.017). As to the
subscores of PDAI, the clinical, endoscopic and histological
subscores were shown to have significant association with the
MMP-9 concentration (p = 0.009, p = 0.011, p = 0.002,
respectively). However, only a weak correlation was revealed
between FC and MMP-9 concentrations (r = 0.449,
p = 0.054) (FIGURE 5). Fecal MMP-9 was determined in
21 patients (eight patients with pouchitis and 13 patients
without pouchitis).
Correlation between FC & MMP-9 concentrations & cuffitis
No association was revealed between FC and MMP-9 and the
presence of cuffitis or stenosis either in patients with or
without pouchitis.
Correlation between pouchitis &the inflammatory labora-
tory parameters
None of the laboratory markers correlated significantly
with pouchitis.
Discussion
Pouchitis is an idiopathic chronic inflammatory disease that
may occur in the ileal pouch after restorative proctocolectomy
with IPAA and has a significant effect on the patients’ quality
of life. Detecting consistently available, non-invasive factors to
predict, determine and follow-up pouchitis is extremely impor-
tant and has a high clinical value in the selection of an appropri-
ate treatment. In this prospective, pilot study, the median FC
level was more than fivefold higher; the median MMP-9 level
was almost 12 times higher in patients with versus without
pouchitis, although a significant correlation was revealed only
between fecal MMP-9 and the severity of pouchitis.
FC and MMP-9 are promising non-invasive diagnostic
inflammatory markers not only in UC, but also in pouchitis,
although only a few studies examined their diagnostic accu-
racy in pouchitis. In one of the first studies in this topic,
Johnson et al. revealed the ability of FC to differentiate
between inflamed and non-inflamed pouches. A close correla-
tion was also shown between FC concentrations and acute
histological and endoscopic inflammation and PDAI [14].
Although, in the study of Thomas et al., FC concentration,
at a cut-off of 10 mg/l, had a sensitivity of 100 and a speci-
ficity of 87% in diagnosing pouchitis, the different methodi-
cal procedure may explain the different (higher) cut-off value
that was determined in our study [15]. Pakarinen et al.
revealed a significant difference in mean FC concentration
between patients with no history of pouchitis and those with
recurrent pouchitis [16]. They showed that FC correlated pos-
itively with the histological neutrophil count of the distal
ileum, the frequency of pouchitis and the maximum daily
frequency of bowel actions.
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Figure 2. Receiver operating characteristic curve with AUC
of 0.78 showed the cut-off value of FC of 262 mg/g with
the sensitivity and specificity of 67 and 89% in the
diagnosis of pouchitis.
ROC: Receiver operating characteristic.
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Figure 1. Median fecal calprotectin concentration was
significantly higher in patients with versus without
pouchitis. Y-axis shows the range of FC (range: 0–3000;
minimum: 30; maximum: 3000 mg/g).
FC: Fecal calprotectin.
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Figure 3. Median fecal MMP-9 concentration was signifi-
cantly higher in patients with versus without pouchitis.
Y-axis shows the range of fecal MMP-9 (range: 0–46.9;
minimum: 0.05; maximum: 46.9 ng/ml).
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While the diagnostic role of FC in pouchitis has previously
been examined in some studies, only limited data are available
on the role of MMP-9 in pouchitis, and it has never been used
as a diagnostic stool marker in this disease. MMPs take part in
normal mucosal defense and play a role in the development of
inflammatory processes, as well as in the pathogenesis of
inflammatory diseases [17]. In IBD, MMP-9 is the most abun-
dantly expressed MMP, and it shows increased activity in
inflamed UC mucosa and in pouchitis [18]. In case of pediatric-
onset UC patients, most pouch samples showed an increased
expression of MMP-3 and MMP-7 in pouchitis, which do not
correlate with the markers of inflammation, FC, erythrocyte
sedimentation rate or CRP [19].
The role of mucosal MMPs in the differentiation of pouchi-
tis was first examined by Stallmach et al. [20]: they revealed
that MMP-1 and MMP-2 concentrations in the mucosal
biopsy samples were increased in pouchitis compared with
uninflamed pouches of patients with UC or familial adenoma-
tous polyposis. Strong MMP-9 and MMP-2 activity was
detected in the inflamed pouch being reduced after antibiotic
treatment in the study of Ulisse et al. [21]. However,
MMP-9 has never been assessed in the stool of patients with
IPAA. In the present study, we evaluated the diagnostic accu-
racy of FC and MMP-9 in pouchitis. Our results revealed that
none of the routinely used laboratory activity markers corre-
lated significantly with pouchitis, but the levels of FC and
MMP-9 were significantly increased in pouchitis. Moreover,
fecal MMP-9 showed a significantly stronger correlation with
the severity of pouchitis than FC did, and it correlated even
more significantly with the clinical, endoscopic and histological
activity of pouchitis. Interestingly, histological examinations
usually showed cryptitis, abnormal crypt structure or even crypt
abscess and described the findings as an UC-like image, con-
firming a colonic-type mucosa in patients with moderate-to-
severe pouchitis with higher MMP-9 levels. In case of pouchitis
with only mild activity and lower MMP-9, the histological
finding described the characteristic of the inflammation as
an ileitis.
The authors are aware of the limitations of the study. The
main restriction of the study is the low number of enrolled
patients, although nearly the same or lower numbers of patients
participated in the previously mentioned studies. However, it
should be noted that the frequency of colectomy in UC is
somewhat lower in Hungary than in the Western and North-
ern countries, and we enrolled almost half of the patients
treated at our centre that had been operated on throughout the
past 10 years. According to our previously published data, the
overall colectomy rate was 24.6% at our centre during a 7-year
period [22]. However, the strengths of this study are the accu-
rately performed diagnostic and scoring procedures.
This is the first pilot study that assesses the diagnostic accuracy
of FC and MMP-9 in pouchitis. Our results show that although
both fecal markers are elevated in pouchitis, fecal MMP-9 has
higher specificity in the detection of pouchitis. However, none of
them are associated with cuffitis that presents with similar
symptoms as pouchitis. These non-invasive methods help assess
pouch inflammation, differentiate between pouchitis and cuffitis
and, therefore, optimize future management.
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Figure 4. Receiver operating characteristic curve with AUC
of 0.89 showed the cut-off value of fecal MMP-9 of
3.85 ng/ml with the sensitivity and specificity of 89 and
91% in the diagnosis of pouchitis.
ROC: Receiver operating characteristic.
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Figure 5. Correlation between fecal calprotectin and matrix
metalloprotease-9 levels. FC and fecal MMP-9 determinations
were available in 21 patients. R-value = 0.549.
FC: Fecal calprotectin; MMP-9: Matrix metalloprotease-9.
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Key issues
• The incidence of pouchitis after total proctocolectomy with ileal pouch-anal anastomosis is high.
• The gold standard for assessing pouchitis is endoscopy.
• Only limited data are available on the diagnostic accuracy of fecal calprotectin and in pouchitis.
• Sensitivity of fecal matrix metalloprotease-9 (MMP-9) has never been examined in pouchitis.
• Our study revealed that both fecal calprotectin and fecal MMP-9 concentrations were significantly higher in patients with versus without
pouchitis. However, a significant correlation was revealed only between fecal MMP-9 and the severity of pouchitis.
• Fecal MMP-9 seems to have higher specificity in the detection of pouchitis.
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